Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202844 | 0.77 | TSHR (0.37) | TSHRSMN1; SMN2 | |
| SCHEMBL5432873 | 0.74 | AGER (0.38) | — | |
| Dimethylamine SCHEMBL1861764 | 0.73 | KDM4E (0.38) | KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL584954 | 0.73 | TSHR (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL585273 | 0.72 | MAOA (0.34) | SMN1; SMN2 | |
| SCHEMBL28713240 | 0.72 | PLA2G2A (0.36) | TSHR | |
| SCHEMBL2330211 | 0.72 | KDM4E (0.32) | KDM4E | |
| SCHEMBL2360345 | 0.71 | CYP1A2 (0.32) | TSHRSMN1; SMN2 | |
| SCHEMBL584885 | 0.71 | TSHR (0.50) | TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL586081 | 0.71 | KDM4E (0.31) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | disclosed |
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| EP-1897883-A2 | Cationic porphyrin derivatives as antibacterial agents | Destiny Pharma Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | DESTINY PHARMA LIMITED | 2007-12-06 | — | — | US | disclosed |
| EP-1578750-B1 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | DESTINY PHARMA LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-20040143001-A1 | Novel compounds and uses thereof | DESTINY PHARMA LIMITED | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143001-A1 | Novel compounds and uses thereof | PPOX, CYP19A1, XDH | TSHR 3602/4885KDM4E 1792/4885SMN1; SMN2 3123/4885 |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | PPOX, PPIF, TYR | TSHR 2764/4885KDM4E 1845/4885SMN1; SMN2 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.